Fienberg
Allen Fienberg, New York, NY US
Patent application number | Description | Published |
---|---|---|
20110071080 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 03-24-2011 |
20110312978 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS - Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used. | 12-22-2011 |
20140050783 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 02-20-2014 |
Allen A. Fienberg, New York, NY US
Patent application number | Description | Published |
---|---|---|
20100087450 | ORGANIC COMPOUNDS - The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and/or prophylaxis of narcolepsy. | 04-08-2010 |
20100323997 | NOVEL USES - The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction. | 12-23-2010 |
Garrett W. Fienberg, New York, NY US
Patent application number | Description | Published |
---|---|---|
20080243421 | Method and System for Measuring Energy Savings Resultant from Improvements Made to a Structure - A method and related system for determining energy savings that result from improvements made to a structure includes auditing the structure before the improvements are made to create a mockup of a section of the unimproved structure. The structure is then fully improved, and the mockup is disposed near a region of the improved structure that is to be monitored. The mockup may be thermally isolated from the improved region. An energy-related value, such as temperature, is then measured from the mockup and from the improved region of the structure. The mockup provides a baseline value, while the improved region provides a post-improvement value. Utilizing these measured values, the energy savings resulting from the improvement made to the structure can be determined. | 10-02-2008 |
Harris G. Fienberg, Stanford, CA US
Patent application number | Description | Published |
---|---|---|
20140329272 | Metal-Based Covalent Viability Reagent for Single Cell Analysis - The present invention provides a robust viability stain for methods utilizing elemental analysis. A population of cells is contacted with an effective dose of a non-chelated biomacromolecule-reactive metal derivative, which selectively crosses the plasma membrane of non-viable cells, and which covalently modifies a biological macromolecule within the cell, for a period of time sufficient to permit entry into non-viable cells. The population of cells is then washed free of unbound viability reagent; and the presence of the metal within the cells is detected, wherein non-viable cells are selectively labeled with the viability reagent. | 11-06-2014 |
Ron Fienberg, Simi Valley, CA US
Patent application number | Description | Published |
---|---|---|
20080258882 | POWERLINE CONTROL SYSTEM AND METHOD - Circuits and methods for transmission of digital data between two or more devices via powerline particularly suited for use in high attenuation, high noise commercial/industrial powerline environments, including transmission of pulses generated by a capacitor charged in the positive half cycle of the sine wave and discharged during the negative half-cycle, placing the pulse at one of two predetermined signal timing positions related to zero voltage crossing points or to previously transmitted pulses so that the pulses are substantially in the powerline temporal quiet zone near zero crossing and so that the powerline voltage at the time of the pulse is additive to the capacitor voltage. | 10-23-2008 |